Commentary Although many improvements have been made regarding the prevention of post-surgical infection during the last few decades, implant-related infections remain an important and challenging clinical problem. With the ever-increasing number of total joint arthroplasties implanted annually and the increasing emergence of antibiotic-resistant bacteria, this challenge will be even greater in the near future. Whereas most resistant bacteria can still be treated with last-resort antibiotics such as linezolid and carbapenems, more and more multiresistant species for which there is currently no available antibiotic treatment are being found. This forces us to look at antimicrobial options outside of the traditional field of antibiotics. The efficacy of various potential new strategies has already been investigated in vitro and in vivo. These strategies included the use of antiseptics, antimicrobial peptides, silver, and autologous platelet-rich gel. Most studies have investigated the efficacy of these strategies in the prevention of implant-related infections rather than the treatment of such infections. Despite the promising results of some strategies, almost none have reached the clinical application phase.

The authors of the current study investigated another novel strategy against implant-related infections—the use of bacteriophages as antimicrobial agents. Although the use of bacteriophages for this particular indication is novel, the use of bacteriophages to treat infection is actually a technique that is almost a century old. Although this technique never gained worldwide popularity because of the discovery of antibiotics, bacteriophages have been used to treat different kinds of infections in many countries of the former Soviet Union. This treatment is based on the nature of bacteriophages, which are viruses that invade bacterial cells and inject part of their genome, thereby taking over the bacterium’s metabolic activity. This enables them to replicate themselves and to produce specific proteins, called endolysins, which ultimately kill the bacterium. In addition to lysing the bacterial cell wall, these endolysins would be able to destroy the polysaccharide matrix of biofilms.

The authors present a well-designed in vivo study that uses a previously developed implant-related animal infection model. The implant material used was a plastic catheter sheath, which was both precolonized and locally contaminated at the time of implantation. The authors studied the activity of two different bacteriophages, against biofilm-forming methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa, and compared the results of the bacteriophage treatment with no treatment, adequate antibiotic treatment, and combined bacteriophage and antibiotic treatment. The outcomes studied were infection markers in blood, microbiology, and histopathology using both light and electron microscopy. The results showed that, for MRSA, the antibiotic therapy and the bacteriophage therapy were each effective in decreasing the number of cases in which bacteria were still seen and in decreasing the quantitative number of bacteria (although the decreases in the bacteriophage group did not reach significance). However, the combination of antibiotics and bacteriophages was the most effective, suggesting a synergistic effect. The combination therapy not only eradicated almost all bacteria but also completely destroyed the biofilm. An interesting finding was the large increase in biofilm thickness in the group treated with antibiotic therapy; this may illustrate the fact that many antibiotics are effective in killing the free-floating bacteria but do not influence the adherent bacteria inside the polysaccharide matrix of the biofilm. For Pseudomonas aeruginosa, the effect of the bacteriophage treatment was less pronounced. Although there was a significant decrease in the number of bacteria found, most of the rats in each group remained infected, and there was no decrease in the biofilm thickness.